Last reviewed · How we verify
sofosbubir/velpatasvir
Sofosbuvir inhibits hepatitis C virus NS5B polymerase while velpatasvir inhibits NS5A protein, together blocking viral replication.
Sofosbuvir inhibits hepatitis C virus NS5B polymerase while velpatasvir inhibits NS5A protein, together blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, all genotypes, with or without cirrhosis.
At a glance
| Generic name | sofosbubir/velpatasvir |
|---|---|
| Also known as | Epclusa |
| Sponsor | Partners in Health |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5B polymerase and NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Sofosbuvir is a nucleotide analog that acts as a chain terminator of the HCV NS5B RNA-dependent RNA polymerase, preventing viral RNA synthesis. Velpatasvir is a non-structural protein 5A (NS5A) inhibitor that disrupts viral replication and assembly. Together, this fixed-dose combination provides direct-acting antiviral activity against multiple HCV genotypes.
Approved indications
- Chronic hepatitis C virus (HCV) infection, all genotypes, with or without cirrhosis
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |